HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions for remote cardiac care, has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report (https://ibn.fm/ZuLCr). The company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only GE Healthcare. This recognition underscores HeartBeam's growing influence in the next generation of cardiac monitoring technology.
HeartBeam's ranking underscores the rapid maturation of the company's proprietary synthesis-ECG system, which captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG. This unique approach allows physicians to obtain comprehensive cardiac data from a portable device, potentially improving the detection and monitoring of critical cardiac conditions outside traditional clinical settings.
The company's intellectual-property foundation is a major reason for its placement. HeartBeam holds over 20 issued patents related to its technology enablement, and its 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024. The 12-Lead ECG synthesis software is currently under FDA review, which could further expand the company's capabilities in remote cardiac care.
The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead (in three directions) ECG acquired from 5 electrodes. The device is intended for use by adult patients in either a clinical setting or at home. It does not conduct cardiac analysis and can be used with an ECG Viewer software system for manual interpretation of non-life-threatening arrhythmias by a physician or healthcare professional. For full safety information, see the full Instructions for Use or Clinician Portal Manual.
This recognition from PatentVest positions HeartBeam as a key player in the portable ECG market, which is expected to grow as remote patient monitoring becomes more prevalent. The company's technology aims to deliver actionable heart intelligence, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities.
HeartBeam's achievement highlights the importance of innovation in cardiac diagnostics and the potential for portable devices to transform patient care. As the company continues to develop its synthesis-ECG platform, it may play a significant role in redefining the future of cardiac health management.
